Skip to main content

Market Overview

Abbott's Molecular Assay Gets FDA EUA Approval To Detect SARS-CoV-2 And Flu In One Test

  • The FDA has granted Emergency Use Authorization (EUA) for Abbott Laboratories' (NYSE: ABT) Alinity m Resp-4-Plex molecular assay to detect and differentiate SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV) in one test.
  • The Alinity m Resp-4-Plex test can be conducted with one swab specimen.
  • The company announced that EUA for the Alinity m SARS-CoV-2 test had been updated to include an asymptomatic claim, detecting COVID-19 in individuals who do not have symptoms.
  • EUA was also updated to include a pooling claim, which allows testing up to five samples simultaneously. 
  • The Alinity m system can run up to 1,080 tests in a 24-hour period based on laboratory practice and workflow. 
  • Price Action: ABT shares are trading 0.83% lower at $115.06 in market trading hours on the last check Friday.

Related Articles (ABT)

View Comments and Join the Discussion!

Posted-In: Covid-19Biotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at